R-Biopharm and Merck Partner on Companion Diagnostics

By LabMedica International staff writers
Posted on 10 Apr 2016

R-Biopharm AG (Darmstadt, Germany) and Merck KGaA (Darmstadt, Germany) have entered into an agreement that constitutes their first collaboration, which will initially focus on developing and launching companion diagnostics.

Companion diagnostics play a central role in personalized medicine by helping to find specific therapies matching to individual patients and thereby improve patient care and reduce healthcare costs.

In addition to covering research, development, and launching of novel companion diagnostics, the project also provides a framework for further collaborations across a potentially wide range of therapeutic areas and a broad range of technologies.

"We are very pleased to partner with Merck KGaA, Darmstadt, Germany, one of the world's leading healthcare companies", said Dr. Frank Apostel, vice president, Companion Diagnostics, R-Biopharm, a leading developer and provider of reliable test systems for clinical diagnostics and for analyzing human food and animal feedstuffs, "This partnership is an example to the level of expertise and service R-Biopharm is committed to delivering to our partners in companion diagnostics."

Financial terms of the agreement were not disclosed.

Related Links:
R-Biopharm
R-Biopharm Companion Diagnostics
Merck KGaA